Tradestie Institutional Equity Comparison Engine
CONX vs ABVC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABVC Overall Edge
ABVC Captures Institutional Edge (2โ0 Pillars ยท 7โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ABVC BioPharma, Inc. Common Stock (ABVC) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, CONX trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ABVC at N/M Forward P/E and 0.0% operating margin (+104.5% YoY). In options structure, CONX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ABVC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CONX N/M vs ABVC N/M Fwd P/E
Growth & Margin Winner
ABVC
Op Margin N/A vs 0.0% ยท YoY N/A vs +104.5%
Momentum & Technical Winner
ABVC
1Y -89.0% vs -66.4% ยท 52W Pos 0% vs 10%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
CONX
US Equity
CONX
Institutional Equity
$2.66
-11.75% 1D
Market Cap
N/A
1M Return
-54.66%
1Y Return
-88.97%
Forward P/E
N/M
Unified AI Score
42.0 / 100
HOLD
Tech 25.0
Fund 54.0
Flow 50.0
Mom 55.0
ABVC
NASDAQ
ABVC BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$0.94
+3.3% 1D
Market Cap
$24.5M
1M Return
+2.41%
1Y Return
-66.43%
Forward P/E
N/M
Unified AI Score
39.0 / 100
SELL
Tech 32.0
Fund 37.0
Flow 50.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CONX -88.97%
ABVC -66.43%
Spread: +23.53 pp (ABVC Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CONX TTM Op. Margin: N/A
ABVC TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CONX vs ABVC. Trailing 12-month operating profitability (CONX N/A vs ABVC 0.0%) and valuation multiples (CONX N/M vs ABVC N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CONX | ABVC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $24.5M | Larger Scale | ABVC |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | +104.5% | Higher Growth | ABVC |
| Operating Margin (TTM) Profitability | N/A | 0.0% | Higher Margin | ABVC |
| Net Profit Margin Profitability | N/A | 0.0% | Higher Margin | ABVC |
| Return on Equity (ROE) Capital Efficiency | N/A | -52.7% | Higher ROE | ABVC |
| 52-Week Range Position Momentum | 0% ($3โ$28) | 10% ($1โ$3) | Stronger Trend | ABVC |
| Beta / 30D Volatility Risk Regime | 4.88ฮฒ ยท 135% Vol | 1.34ฮฒ ยท 56% Vol | Lower Realized Risk | ABVC |
| Unified Institutional Score Composite Signal | 42.0 / 100 (HOLD) | 39.0 / 100 (SELL) | Higher Composite | CONX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CONX vs ABVC Buy Guide
CONX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
ABVC
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CONX nor ABVC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.